Trimeris acquisition offer extended to Dec. 28
Trimeris
Related Blog Posts
- South Korean firm to pay $81M for Trimeris, developer of HIV drug Fuzeon
- South Korean firm formally launches buyout of Trimeris
- Trimeris shares fall 18% after S.K. buyer asks for extenstion
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter
Local Tech Wire
DURHAM, N.C. — Trimeris (Nasdaq: TRMS) and the Korean company that is poised to buy the drug developer have agreed to extend an offer for Trimeris shares until Dec. 28, and Trimeris will get $12 million it was due if the deal fell through.
Arigene Co. Ltd. offered $3.60 a share for Trimeris in early October, and the deadline for closing the deal was Monday evening. Arigene said it had received offers for 82.7 percent of Trimeris' shares by then.
The new deadline is 5 p.m. Eastern Standard Time on Dec. 28.
Trimeris and Arigene noted in their announcement that Arigene agrees to go through with the purchase regardless of anything that happens at Trimeris between now and the deadline.
Trimeris is the developer of the HIV drug Fuzeon. Its stock was up over 5 percent Tuesday to $3.13 a share at the market's close.
Arigene develops, manufactures and markets Ubiquitous Healthcare Systems (U-Healthcare) and related medical equipment in Korea. Acquiring Trimeris is an extension into biotech.
Copyright 2012 WRAL Tech Wire. All rights reserved.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
- Redbox-Verizon streaming plan to crowd online video space
E-mail Preferences
The Skinny
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO